Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors.
Chirine RafiaChristelle HarlyEmmanuel ScotetPublished in: Immunological reviews (2020)
Despite recent significant progress in cancer immunotherapies based on adoptive cell transfer(s)(ACT), the eradication of cancers still represents a major clinical challenge. In particular, the efficacy of current ACT-based therapies against solid tumors is dramatically reduced by physical barriers that prevent tumor infiltration of adoptively transferred effectors, and the tumor environment that suppress their anti-tumor functions. Novel immunotherapeutic strategies are thus needed to circumvent these issues. Human peripheral blood Vγ9Vδ2 T cells, a non-alloreactive innate-like T lymphocyte subset, recently proved to be a promising anti-tumor effector subset for ACT-based immunotherapies. Furthermore, new cell engineering tools that leverage the potential of CRISPR/Cas technology open astounding opportunities to optimize their anti-tumor effector functions. In this review, we present the current ACT strategies based on engineered T cells and their limitations. We then discuss the potential of engineered Vγ9Vδ2 T cell to overcome these limitations and improve ACT-based cancer immunotherapies.
Keyphrases
- peripheral blood
- cell therapy
- crispr cas
- papillary thyroid
- single cell
- immune response
- induced apoptosis
- endothelial cells
- squamous cell
- genome editing
- dendritic cells
- childhood cancer
- regulatory t cells
- physical activity
- type iii
- stem cells
- cell cycle arrest
- mental health
- squamous cell carcinoma
- signaling pathway
- minimally invasive
- young adults
- cell death
- human health
- endoplasmic reticulum stress
- induced pluripotent stem cells